Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | MMP2 | P08253 | 4/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | MGAM | O43451 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7143621 | 1.00 | KDM4E (0.68) | KDM4EKMT2AMMP2ALOX15TSHR | |
| SCHEMBL28798022 | 0.98 | KDM4E (0.66) | KDM4EKMT2AMMP2ALOX15TSHR | |
| SCHEMBL27283354 | 0.98 | KDM4E (0.66) | KDM4EKMT2AMMP2ALOX15TSHR | |
| SCHEMBL8490359 | 0.87 | PIM1 (0.65) | KDM4EKMT2AMMP2ALDH1A1LMNA | |
| Benzene SCHEMBL27872024 | 0.83 | KDM4E (0.70) | KDM4EKMT2AMMP2ALOX15TSHR | |
| Benzene SCHEMBL27888317 | 0.81 | KDM4E (0.68) | KDM4EKMT2AMMP2ALOX15TSHR | |
| SCHEMBL1088781 | 0.81 | KDM4E (0.67) | KDM4EKMT2AMMP2ALOX15TSHR | |
| SCHEMBL29697210 | 0.81 | KDM4E (1.00) | KDM4EKMT2AMMP2ALOX15TSHR | |
| SCHEMBL171491 | 0.81 | KDM4E (1.00) | KDM4EKMT2AMMP2ALOX15TSHR | |
| SCHEMBL1697008 | 0.81 | ALDH1A1 (0.50) | KDM4EKMT2AALOX15TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115611932-B | Preparation and application of dicarboxylic acid derivative capable of serving as GPR35 receptor fluorescent probe | 中国科学院大连化学物理研究所 | 2025-01-14 | — | — | CN | claimed |
| US-20250213569-A1 | METHODS AND COMPOSITIONS FOR MEASURING AND INHIBITING EXONUCLEASE ACTIVITY | NEW YORK UNIVERSITY (US) | 2025-07-03 | — | — | US | disclosed |
| CN-115611932-B | Preparation and application of dicarboxylic acid derivative capable of serving as GPR35 receptor fluorescent probe | 中国科学院大连化学物理研究所 | 2025-01-14 | — | — | CN | disclosed |
| CN-116897051-A | Plasmin peptides for increasing therapeutic index | 诺诺公司 | 2023-10-17 | — | — | CN | disclosed |
| CN-115551531-A | Plasmin-cleavable PSD-95 inhibitor and reperfusion combined treatment of stroke | 诺诺公司 | 2022-12-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213569-A1 | METHODS AND COMPOSITIONS FOR MEASURING AND INHIBITING EXONUCLEASE ACTIVITY | DCLRE1B, RNASE1, ADAR | KDM4E 4082/4885KMT2A 4125/4885MMP2 687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.